Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates Zacks - Mon Aug 8, 5:05PM CDT

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 89.66% and 22.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

CSTL : 31.33 (-2.49%)
SYRS : 0.9402 (-3.07%)
Castle Biosciences Reports Second Quarter 2022 Results Business Wire - Mon Aug 8, 3:05PM CDT

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June...

CSTL : 31.33 (-2.49%)
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates Zacks - Thu Aug 4, 8:15AM CDT

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 17.65% and 77.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CCCC : 11.51 (-3.03%)
CSTL : 31.33 (-2.49%)
American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus Business Wire - Thu Aug 4, 6:00AM CDT

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the American Gastroenterological Association (AGA) recently published...

CSTL : 31.33 (-2.49%)
Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference Business Wire - Wed Aug 3, 6:00AM CDT

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank...

CSTL : 31.33 (-2.49%)
Lumos Pharma (LUMO) Expected to Beat Earnings Estimates: Should You Buy? Zacks - Tue Aug 2, 9:00AM CDT

Lumos (LUMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LUMO : 8.85 (+1.72%)
CSTL : 31.33 (-2.49%)
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline Zacks - Mon Aug 1, 9:00AM CDT

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CSTL : 31.33 (-2.49%)
INSM : 26.03 (-1.74%)
Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8 Business Wire - Mon Jul 25, 4:00PM CDT

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and...

CSTL : 31.33 (-2.49%)
DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma Business Wire - Mon Jul 25, 6:00AM CDT

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone for the Company’s DecisionDx®-Melanoma gene...

CSTL : 31.33 (-2.49%)
Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma Business Wire - Wed Jul 20, 6:00AM CDT

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced an upcoming presentation on DecisionDx®-Melanoma, the Company’s...

CSTL : 31.33 (-2.49%)

Barchart Exclusives

Unusual Options Activity Clashes with the Bulls Over Bed Bath & Beyond (BBBY) Barchart - 1 hour ago
Although shares of Bed Bath & Beyond spiked higher due to activist investor Ryan Cohen’s bullish wager, bears see a contrarian opportunity with BBBY stock. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' : 'America/Chicago' ]] CDT
Reserve Your Spot